Northwell opens molecular diagnostics laboratory to identify targeted cancer therapies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Northwell Health Cancer Institute and its Center for Genomic Medicine opened Long Island’s first clinical Molecular Diagnostics Laboratory, a $3.2 million 2,800 square foot state-of-the-art facility with technology of next-generation sequencing that provides point-of-care tumor and patient genomic profiling to inform precision cancer therapy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient undergoes surgery, and cancer stage at diagnosis continues to be a leading factor in determining a person’s survival rate for all types of cancer, according to the first-ever annual cancer report from the National Cancer Database.
Marking a new era of non-invasive medical interventions, the Northwell Health Cancer Institute is investing $1.2 million in the development of cutting-edge histotripsy technology to treat some liver cancer tumors without surgery. This innovative approach uses targeted ultrasound beams to create microbubbles within tumors, effectively disrupting and destroying diseased cells without the need for incisions.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login